- Home
- MTLS vs IFRX Comparison
MTLS vs IFRX Comparison
Compare MTLS & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MTLS | IFRX |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | Belgium | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.9M | 303.4M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MTLS | IFRX |
|---|---|---|
| Price | $6.74 | $2.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 109.3K | ★ 1.5M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.38 | N/A |
| Revenue Next Year | $6.45 | N/A |
| P/E Ratio | $61.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.78 | $0.74 |
| 52 Week High | $7.50 | $2.95 |
Technical Indicators
Market Signals| Indicator | MTLS | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 49.69 |
| Support Level | $6.40 | $0.93 |
| Resistance Level | $6.89 | $2.94 |
| Average True Range (ATR) | 0.27 | 0.23 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 12.78 | 23.42 |
Price Performance
Historical ComparisonAbout MTLS Materialise NV
Materialise NV is a provider of 3D-printed medical devices and software and a pioneer in additive manufacturing software and services. The company operates through three principal segments: Materialise Software, Materialise Medical, and Materialise Manufacturing, with the Materialise Medical segment generating maximum revenue. The Materialise Medical segment develops and delivers medical software solutions, medical devices, and related products and services; the Materialise Software segment develops and delivers additive manufacturing software solutions and related services; and the Materialise Manufacturing segment delivers 3D-printed products and related services. The company generates maximum revenue from the United States of America.
About IFRX InflaRx N.V.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.